HNRNPA2B1-mediated m6A modification of lncRNA MEG3 facilitates tumorigenesis and metastasis of non-small cell lung cancer by regulating miR-21-5p/PTEN axis
Journal of Translational Medicine,
Journal Year:
2023,
Volume and Issue:
21(1)
Published: June 12, 2023
Abstract
Background
Accumulating
data
indicate
that
N6-methyladenosine
(m
6
A)
RNA
methylation
and
lncRNA
deregulation
act
crucial
roles
in
cancer
progression.
Heterogeneous
nuclear
ribonucleoprotein
A2B1
(HNRNPA2B1)
as
an
m
A
“reader”
has
been
reported
to
be
oncogene
multiple
malignancies.
We
herein
aimed
elucidate
the
role
underlying
mechanism
by
which
HNRNPA2B1-mediated
modification
of
lncRNAs
contributes
non-small
cell
lung
(NSCLC).
Methods
The
expression
levels
HNRNPA2B1
their
association
with
clinicopathological
characteristics
prognosis
NSCLC
were
determined
RT-qPCR,
Western
blot,
immunohistochemistry
TCGA
dataset.
Then,
cells
was
assessed
vitro
functional
experiments
vivo
tumorigenesis
metastasis
models.
screened
A-lncRNA
epi-transcriptomic
microarray
verified
methylated
immunoprecipitation
(Me-RIP).
MEG3-specific
binding
miR-21-5p
evaluated
luciferase
gene
report
RIP
assays.
effects
(or)
MEG3
on
miR-21-5p/PTEN/PI3K/AKT
signaling
examined
RT-qPCR
blot
analyses.
Results
found
upregulation
associated
distant
poor
survival,
representing
independent
prognostic
factor
patients
NSCLC.
Knockdown
impaired
proliferation
vivo,
whereas
ectopic
possessed
opposite
effects.
Mechanical
investigations
revealed
target
inhibition
decreased
but
increased
its
mRNA
levels.
Furthermore,
could
a
sponge
upregulate
PTEN
inactivate
PI3K/AKT
signaling,
leading
suppression
invasion.
Low
or
elevated
indicated
survival
Conclusions
Our
findings
uncover
promotes
regulating
miR-21-5p/PTEN
axis
may
provide
therapeutic
for
Language: Английский
Lipid Nanoparticles-Based Therapy in Liver Metastasis Management: From Tumor Cell-Directed Strategy to Liver Microenvironment-Directed Strategy
International Journal of Nanomedicine,
Journal Year:
2023,
Volume and Issue:
Volume 18, P. 2939 - 2954
Published: June 1, 2023
Abstract:
Metastasis
to
the
liver,
as
one
of
most
frequent
metastatic
patterns,
was
associated
with
poor
prognosis.
Major
drawbacks
conventional
therapies
in
liver
metastasis
were
lack
metastatic-targeting
ability,
predominant
systemic
toxicities
and
incapability
tumor
microenvironment
modulations.
Lipid
nanoparticles-based
strategies
like
galactosylated,
lyso-thermosensitive
or
active-targeting
chemotherapeutics
liposomes
have
been
explored
management.
This
review
aimed
summarize
state-of-art
lipid
Clinical
translational
studies
on
nanoparticles
treating
searched
up
April,
2023
from
online
databases.
focused
not
only
updates
drug-encapsulated
directly
targeting
cancer
cells
metastasis,
but
more
importantly
research
frontiers
drug-loading
nonparenchymal
components
which
showed
promise
for
future
clinical
oncological
practice.
Keywords:
neoplasms,
neoplasm
liposomes,
Language: Английский